Ownership and insider activity for Lexaria Bioscience Corp. (LEXX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream.
Price
| Price | $3.10 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | CA |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-03-17 | BUNKA CHRISTOPHER | G-Gift | 100,000 | |
| 2025-07-30 | BUNKA CHRISTOPHER | P-Purchase | 11,900 | $11K |
| 2025-07-29 | BUNKA CHRISTOPHER | P-Purchase | 15,600 | $14K |
| 2025-07-29 | McKechnie William Edward | P-Purchase | 5,000 | $5K |
| 2025-07-29 | DOCHERTY JOHN MARTIN | P-Purchase | 5,376 | $5K |
| 2025-07-29 | Carle Vanessa | P-Purchase | 750 | $682 |
| 2025-07-29 | CHRISTOPHER RICHARD | P-Purchase | 15,000 | $14K |
| 2025-05-15 | CHRISTOPHER RICHARD | A-Award | 150,000 | $156K |
| 2025-05-15 | BUNKA CHRISTOPHER | A-Award | 11,000 | $11K |
| 2025-05-15 | Carle Vanessa | A-Award | 15,000 | $16K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $93409 | $2.5M | $1.7M | $1.3M | $1.3M | $10.9M | $5.8M | $1.4M | $6.5M | $1.8M |
| Short-term Investments | 0 | 0 | $10151 | $64214 | $19321 | $833841 | $347335 | $125642 | $55807 | $165360 |
| Receivables | $131083 | $45293 | $265751 | $273145 | $313925 | $342401 | $201784 | $175245 | $154477 | $174000 |
| Inventory | $134724 | $67174 | $87233 | $127396 | $116871 | $29648 | $38418 | 0 | 0 | 0 |
| Total Current Assets | $510166 | $2.8M | $2.3M | $1.8M | $1.9M | $12.4M | $7.0M | $2.2M | $7.9M | $3.5M |
| Property, Plant & Equipment | $2475 | $1856 | $1237 | $591263 | $610277 | $459254 | $367949 | $421589 | $389552 | $334945 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $53997 | $62827 | $146538 | $265127 | $292000 | $364623 | $488462 | $462625 | $516676 | $307818 |
| Total Assets | $566638 | $2.9M | $2.4M | $2.7M | $2.8M | $13.3M | $7.8M | $3.1M | $8.9M | $4.2M |
| Accounts Payable | $90010 | $32574 | $14378 | $31463 | $45080 | $104891 | $120146 | $225038 | $1.1M | $1.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $7926 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $433881 | $92347 | $43640 | $184507 | $225917 | $153276 | $194036 | $267735 | $1.1M | $1.5M |
| Long-term Debt | $45000 | 0 | 0 | 0 | $30670 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $478881 | $92347 | $43640 | $184507 | $345980 | $203265 | $201437 | $403908 | $1.2M | $1.6M |
| Retained Earnings | -$11.3M | -$13.2M | -$19.8M | -$23.9M | -$27.8M | -$31.8M | -$39.1M | -$45.8M | -$51.6M | -$63.5M |
| Total Equity | $266045 | $3.0M | $2.4M | $2.4M | $2.5M | $13.3M | $7.9M | $3.0M | $8.0M | $3.0M |
| Total Debt | $45000 | $42690 | $7855 | 0 | $156101 | $97319 | $49988 | $163967 | $137366 | $109320 |
| Net Debt | -$48409 | -$2.5M | -$1.7M | -$1.3M | -$1.2M | -$11.7M | -$6.1M | -$1.3M | -$6.4M | -$1.9M |
| Working Capital | $76285 | $2.7M | $2.2M | $1.6M | $1.7M | $12.3M | $6.8M | $1.9M | $6.8M | $2.0M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 10.60 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -23.89 |
Profitability
| Return on Equity | -160.72% |
| Return on Invested Capital | -173.96% |
| Return on Assets | -161.71% |
| Gross Margin | 100.00% |
| Operating Margin | -3973.16% |
| Net Margin | -3985.58% |
Related companies: ALLR · BCTX · CASI · CING · CLSD · CRIS · ENTO
Explore sector: Healthcare · Biotechnology
More sections of LEXX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks